상세검색
최근 검색어 전체 삭제
다국어입력
즐겨찾기0
학술저널

[특집] 범불안장애 약물치료의 최신 경향

Recent Advances in the Pharmaeotherapy of Generalized Anxiety Disorder

  • 209
커버이미지 없음

Generalized anxiety disorder (GAD), that has been introduced into psychiatric nosology in DSM-III, is characterized by chronic worry that may persist for many years. Pharmacological treatment for GAD includes benzodiazepines, buspirone, and antidepressants. Benzodiazepine have commonly been used for treatment of acute anxiety disorders, but they arc not ideal in the treatment of chronic generalized anxiety disorder (GAD). Buspirone appears to exert benefit primarily on psychic symptoms of anxiety, but the effect of buspirone is slower in onset, taking at least 2 weeks to become evident. Recently, new antidepressants has opened up a new area of investigation into pharmacotherapy of GAD, with a growing body of evidence supporting the role of therapies such as paroxetine and venlafaxine extended release. At present. some selective serotonin reuptake inhibitors such as paroxetine and venlafaxine arc recommended for the best evidence-based approach in the long-term treatment of GAD.

ABSTRACT

서론

범불안장애의 임상적 특징

범불안장애의 약물치료

요약

참고문헌

(0)

(0)

로딩중